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Abstract Ataxin-2 (ATXN2) is implicated mainly in
mRNA processing. Some ATXN2 associates with receptor
tyrosine kinases (RTK), inhibiting their endocytic internali-
zation through interaction of proline-rich domains (PRD) in
ATXN2 with SH3 motifs in Src. Gain of function of ATXN2
leads to neuronal atrophy in the diseases spinocerebellar
ataxia type 2 (SCA2) and amyotrophic lateral sclerosis
(ALS). Conversely, ATXN2 knockout (KO) mice show
hypertrophy and insulin resistance. To elucidate the
influence of ATXN2 on trophic regulation, we surveyed inter-
actions of ATXN2 with SH3 motifs from numerous proteins
and observed a novel interaction with Grb2. Direct binding in
glutathione S-transferase (GST) pull-down assays and coim-
munoprecipitation of the endogenous proteins indicated a
physiologically relevant association. In SCA2 patient fibro-
blasts, Grb2 more than Src protein levels were diminished,
with an upregulation of both transcripts suggesting enhanced
protein turnover. In KO mouse embryonal fibroblasts (MEF),
the protein levels of Grb2 and Src were decreased. ATXN2
absence by itself was insufficient to significantly change
Grb2-dependent signaling for endogenous Ras levels, Ras-
GTP levels, and kinetics as well as MEK1 phosphorylation,
suggesting that other factors compensate for proliferation
control. In KO tissue with postmitotic neurons, a significant
decrease of Src protein levels is prominent rather than Grb2.
ATXN2 mutations modulate the levels of several components
of the RTK endocytosis complex and may thus contribute to
alter cell proliferation as well as translation and growth.
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Introduction
Ataxin-2 (ATXN2) became known as the disease protein of
spinocerebellar ataxia type 2 (SCA2). A trinucleotide repeat
in ATXN2 exon 1, which codes for a polyglutamine (polyQ)
domain, was found to expand from usually 22 U to 32 or
more CAG units and thus cause this multisystem atrophy of
the central nervous system through a gain-of-function mech-
anism (Auburger 2011). Intermediate and large expansions
of 27–37 trinucleotide units, usually CAG repeats with
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CAA interruptions, were recently shown to contribute to the
risk of the motor neuron disease amyotrophic lateral sclero-
sis (ALS) and of the Parkinson plus syndrome Progressive
Supranuclear Palsy (PSP) (Elden et al. 2010; Chen et al.
2011; Daoud et al. 2011; Gispert et al. 2011; Lee et al.
2011a, b; Ross et al. 2011; Soraru et al. 2011; Van Damme
et al. 2011). In animal models, overexpression of ATXN2
potentiates toxicity from neurodegenerative disease proteins
ATXN1, ATXN3, TDP-43, and MAPT, which are responsi-
ble for different variants of spinocerebellar ataxia, ALS,
frontotemporal dementia, and PSP (Shulman and Feany
2003; Al-Ramahi et al. 2007; Lessing and Bonini 2008;
Elden et al. 2010). Moreover, the deficiency of ATXN2
mitigates this toxicity (Elden et al. 2010). Neuroblastoma
tumors are driven into apoptosis by upregulation of ATXN2
(Wiedemeyer et al. 2003). Thus, atrophy of numerous neu-
ronal populations is enhanced by ATXN2 gain of function.
The widespread effects of ATXN2 appear to affect health in
the general population, since a genetic variant in ATXN2
intron 1 is associated with longevity among human cente-
narians (Sebastiani et al. 2010) as well as levels of chronic
blood pressure in independent studies (Levy et al. 2009;
Newton-Cheh et al. 2009). Conversely, the deficiency of
ATXN2 was found to cause mice to grow to excessive size
and weight, through modulation of insulin signaling (Kiehl
et al. 2006; Lastres-Becker et al. 2008a). These findings
raised the notion that ATXN2 is a relevant regulator of
general cell growth.
The amino acid sequence of ATXN2 contains a conspic-
uous PAM2 motif known to mediate interaction with the
cytoplasmic poly(A)-binding protein (PABPC1) as well as a
Lsm and a Lsm-associated domain characterized for their
role in RNA processing (Kozlov et al. 2001; Albrecht and
Lengauer 2004; Ralser et al. 2005a; Satterfield and Pallanck
2006). The subcellular distribution of ATXN2 and its ortho-
logues in other species is mostly cytoplasmic at the rough
endoplasmic reticulum and in association with polysomes or
RNA-containing stress granules (Nonhoff et al. 2007; van
de Loo et al. 2009; Swisher and Parker 2010). This indicates
that ATXN2 modulates RNA translation or RNA turnover,
in good keeping with present concepts that RNA pathology
underlies the motor neuron disease ALS (Lagier-Tourenne
et al. 2010). However, some ATXN2 was detected in the
nuclear and the plasma membrane fractions (Nonis et al.
2008; Hallen et al. 2011), suggesting that it can modulate
cell growth at various steps. Several proline-rich domains
(PRD) within the ATXN2 sequence were observed. They
were found to interact with SH3 motifs within endophilin
A1, CIN85, and Src, three components of the endocytosis
machinery, which forms at the plasma membrane in re-
sponse to growth factor signals stimulating receptor tyrosine
kinases (RTK) such as the epidermal growth factor (EGF)
receptor (Nonis et al. 2008) or as the insulin receptor.
Interfaces between SH3 motifs and PRD are a common way
of protein interaction in endocytosis and also in related cellu-
lar processes of eukaryotic organisms such as signal transduc-
tion or cytoskeleton organization (Fig. 1a). The list of proteins
with SH3motifs implicated in these processes is large; amphi-
physin, actin-binding protein 1, Grb2, intersectin, P85-PI3
kinase, and phospholipase C are just some examples. Thus,
the altered posttranscriptional regulation of insulin receptors
observed in tissues with ATXN2 knockout (KO) (Lastres-
Becker et al. 2008a) might be explained by altered internali-
zation and degradation of the insulin receptor through the
ATXN2 interaction with SH3 proteins. The endocytic inter-
nalization of the EGF receptor was indeed found to be mod-
ulated by ATXN2; it is delayed by ATXN2 overexpression
and enhanced by its deficiency (Nonis et al. 2008).
Trophic factors, which are contained in the serum,
activate RTK to control crucial decisions of cell fate. After
RTK dimerization and autophosphorylation, the kinase Src
is the central hub that initiates signaling in several parallel
cascades (Fig. 1a). The endocytic internalization of activat-
ed RTK was reported to decide which of these pathways is
activated (Goh et al. 2010). Survival, mRNA translation,
and cell growth depend on Src signals via the PI3K/Akt
pathway and also on nutrient availability through the
mTOR pathway. For proliferation, Src signals need to
be transduced by Grb2/SOS via the Ras/Erk pathway
and trigger nuclear transcriptional responses, such as the
activation of c-Jun or ATF2 (Baichwal et al. 1991; Yu
et al. 1993). The crucial RTK endocytosis events are
mediated by association steps between SH3 motif-
containing proteins such as Grb2/CIN85/endophilin A
and PRD in interactors such as Cbl/Sprouty/Alix (Smit
and Borst 1997; Dikic and Giordano 2003; Schmidt and
Dikic 2005). Dozens of interacting proteins allow this
complex to perform a highly regulated control, where
mutations in only few components lead to monogenic
phenotypes, while variants of most components result in
additive polygenic pathology.
In this system, several criteria suggest ATXN2 to act
similarly as Sprouty, since both have PRD, associate with
Cbl, and inhibit endocytosis (Fong et al. 2003; Nonis et al.
2008); are implicated in H-Ras- and K-Ras-mediated cell
transformation (Shaw et al. 2007; Sutterluty et al. 2007;
Holgren et al. 2010; Bertoni et al. 2011); play a role as
tumor suppressors (Wiedemeyer et al. 2003; Taniguchi et
al. 2009); and induce neuronal cell death, while their defi-
ciency favors neuronal survival (Gross et al. 2007; Elden et
al. 2010). ATXN2 also has similarities with Alix, since both
are constitutively associated with the RTK and both inhibit
endocytosis (Schmidt et al. 2004).
Interestingly, ATXN2 contains additional PRD, possibly
to interact with other SH3-motif proteins (Fig. 1b). Exam-
ining the occurrence of further candidate interactors would
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help to clarify the physiological role of ATXN2 in endocy-
tosis and/or in other processes where ATXN2 could be
relevant. To elucidate the precise role of ATXN2 in the
trophic regulation of cell fate, we now studied ATXN2
fragments containing these PRD and tested their interaction
with an array of SH3 motifs from diverse proteins. In
addition, we investigated the question of whether altered
interactions of ATXN2 and SH3-motif proteins affect their
levels to provide mechanistic insight in the effects of
ATXN2 on cell trophism. SCA2 patient cells were used to
test whether the ATXN2 gain of function has relevant effects
on these interactors to explain cell atrophy. Finally, we
sought to determine whether the absence of ATXN2 alone
is able to alter cell proliferation signaling and to explore
whether ATXN2 plays a major role in carcinogenesis. Our
data do support a role of ATXN2 for Src and Grb2 levels but
clearly contradict claims from recent immunofluorescent
studies in a single SCA2 patient fibroblast line that Ras
signaling is modulated strongly, which were published dur-
ing the course of our study (Bertoni et al. 2011).
Results
In Vitro, ATXN2 Binds Diverse SH3 Domains
To screen for ATXN2 association with additional SH3
motifs, commercially available array membranes with 304
spots carrying SH3 motifs from diverse proteins were ex-
posed to HEK-293 protein extracts containing Myc-ATXN2
with the polyQ domain of physiological size (Q22). Several
SH3 motifs bound with varying intensities to the ATXN2
fusion protein (Fig. 1c). A set of proteins was selected for
validation (Table 1), taking into account the ATXN2 binding
strength, the occurrence in the brain, and the antibody
availability.
Fig. 1 ATXN2 interactions with SH3 containing proteins of the RTK-
driven signaling pathways. a Schematic presentation of RTK-driven
pathways. Activated receptor tyrosine kinases stimulate several down-
stream signaling cascades via the activation of Src. The cell fate is
determined depending on the pathway activated. The signals can
maintain survival via PI3K/Akt, the cell can undergo proliferation via
the Grb2/Ras pathway, it can decide to migrate or be driven into
apoptosis via JNK signaling, or its differentiation is modulated via
STAT5 signals. b Schematic representation of ATXN2 highlighting the
proline-rich domains (PXXP) in its amino acid sequence. The arrows
indicate the polyproline domains implicated in the interaction with
endophilin A and the bars indicate the potential regions for interaction
with other SH3 motifs. c Arrays with spotted SH3 motifs identified
numerous candidate interactors of ATXN2 (see Table 1). Membranes
with SH3 motifs from different proteins were incubated with HEK-293
cell extracts with (left side) or without (right side) transfected Myc-
ATXN2. After washing, the membranes were incubated with anti-Myc
antibody. The red square indicates the positions of the Grb2 SH3
Domains #1 and #2
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ATXN2 is Associated with Grb2 in Vivo
To test the physiological association of ATXN2 with our
candidates in mouse brain cytosolic fractions, endogenous
ATXN2 was immunoprecipitated and the proteins of interest
detected. Only the association between endogenous ATXN2
and endogenous growth factor receptor-bound protein 2
(Grb2) could be verified (Fig. 2a). In order to identify the
Grb2 domains needed for the interaction with ATXN2, GST
pull-down assays were carried out. A series of deletion
variants expressing the different domains of Grb2 was gen-
erated as GST fusion proteins (Fig. 2b) and used. ATXN2
with the wildtype (WT) polyQ domain (Q22) was pulled
down only by Grb2 full length and by the carboxy-terminal
SH3 motif, in accordance with the result obtained in the
array (Fig. 2c). Similar results were obtained upon pull-
down of ATXN2 with the pathogenic polyQ expansion
(Q74). These in vitro data suggest that the Grb2 association
is preserved when ATXN2 contains a pathological expan-
sion (Fig. 2d).
ATXN2 PolyQ Expansion Alters Steady-state Levels of Src
and Grb2
To further explore whether the ATXN2 polyQ expansions
implicated in neural atrophy diseases could modify interac-
tion strength, stability, and turnover of the protein complex,
the protein levels of SH3-containing components of the
RTK endocytosis machinery were quantified in primary skin
fibroblasts of four SCA2 patients in comparison to four
Table 1 SH3 motif containing
candidate ATXN2 interactors
selected for Co-IP validation
Array Position Domain Full name
II B1, 2 PI3a Phosphatidylinositol 3-kinase regulatory alpha subunit
II C17, 18 SNX9 Sorting nexin 9
III B1, 2 Grb2-D1 Growth factor receptor-bound protein 2, SH3 Domain #1
III B3, 4 Grb2-D2 Growth factor receptor-bound protein 2, SH3 Domain #2
IV A7, 8 HIP-55 SRC homology 3 domain containing protein HIP-55
IV C15, 16 ARHGEF9 Cdc42 guanine exchange factor 9; hPEM-2 collybistin
IV A1, 2 ITSN(2)-D1 Intersectin 2, Domain #1
IV A5, 6 ITSN(2)-D3 Intersectin 2, Domain #3
Fig. 2 Co-IP analysis of the ATXN2–Grb2 complex. a Endogenous
ATXN2 is associated with endogenous Grb2 in mouse brain. Brain
homogenates were fractionated by differential velocity centrifugation.
The cytosolic fraction was utilized to carry out coimmunoprecipitation
assays with anti-ATXN2 antibody and the corresponding Ig isotype as
control. Immunoblotting was performed using antibodies against
ATXN2 and Grb2. (b–d) Grb2 interacts with ATXN2 through its C-
terminal SH3 motif. b Diagram of human Grb2 and its different
domains. c Myc-ATXN2 overexpressed in HEK-293 cells was incu-
bated with GSH affinity beads charged with GST-Grb2 or fusions with
its respective subfragments. Loading density of GST or GST-fused
proteins on the affinity beads was controlled with anti-GST antibody.
d A repetition of this experiment with overexpressed mutant ATXN2
(Q74) yielded identical results
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healthy matched controls. In view of the inherent growth
differences of untransformed clonal fibroblast lines, the
largest available number of WT vs. mutant cell lines was
compared in the subsequent human and murine studies. A
significant reduction of Grb2 protein to 0.62-fold levels was
observed (Fig. 3a). In testing Src as the crucial established
ATXN2 interactor within the RTK endocytosis machinery
(Nonis et al. 2008), only a trend towards reduction was
apparent for Src protein levels. Since it remained unclear
whether this subtle change exerts a functional effect, the
activation of Src was studied. Src is regulated at the phosphor-
ylation sites Tyr416 and Tyr527 with opposing effects on its
activation (Salter and Kalia 2004). In the inactive state, the
SH2 domain of Src interacts with phosphorylated Tyr527,
while Tyr416 in the activation loop is dephosphorylated. After
dephosphorylation of Tyr527 by protein tyrosine phospha-
tases, the conformation of Src changes, leading to subsequent
autophosphorylation of Tyr416 and a conformational change
of the activation loop, which causes the kinase to be fully
Fig. 3 ATXN2 polyQ expansion alters Grb2 and Src steady-state
levels. Investigation of Grb2 (a) and Src (b) endogenous protein levels
in SCA2 patient skin fibroblasts showed a significant reduction for
Grb2 and a trend towards reduction for Src. The dephosphorylated
state of activating and inhibiting Src sites was increased in parallel. The
mRNA levels showed a trend towards upregulation for GRB2 and
significant upregulation for SRC (four patient fibroblast lines vs. four
control fibroblast lines, n=2 for Western blotting, n=3 for qRT-PCR).
As loading control, β-actin was used in immunoblots, TBP in qRT-
PCR. Representative Western blots are shown for illustration, and
unpaired Student’s t test was used for statistical analysis (*p<0.05;
**p<0.01; ***p<0.001)
Fig. 4 ATXN2 loss of function decreases protein levels of Grb2 and
Src. a In mouse embryonal fibroblasts (MEFs) with ATXN2 knockout
(KO or −/−) vs. littermate wildtype (WT), Grb2 protein levels were
reduced (seven WT vs. eight KO, n=2). In the mixed tissue cerebellum
from adult ATXN2−/−mice, Grb2 protein levels did not differ (nine WT
vs. nine KO). As loading control, β-actin was used in immunoblots. b
In KO-MEFs, Src protein levels were reduced (seven WT vs. eight KO,
n=2). In cerebellum from adult ATXN2−/− mice, a significant decrease
of total Src protein levels was observed (nine WT vs. nine KO). As
loading control, β-actin was used in immunoblots. Representative
Western blots are shown for illustration, and unpaired Student’s t test
was used for statistical analysis (*p<0.05; **p<0.01; ***p<0.001)
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activated. Parallel increases in the dephosphorylated state of
both principal Src sites (Fig. 3b) reflected the altered levels. In
order to understand whether the decreased protein levels are
caused by enhanced protein degradation or reduced pro-
tein synthesis, the mRNA levels were studied and a
trend towards upregulation was observed for GRB2
transcript (Fig. 3a), accompanied by a significant upre-
gulation to 1.29-fold levels for SRC transcript (Fig. 3b),
suggesting that the deficit in steady-state protein levels
prevails in spite of a compensatory upregulation of the
respective mRNAs.
ATXN2 Deficiency Alters the Steady-state Levels of Grb2
and Src
To test whether the levels of SH3-containing interactors
change in the absence of ATXN2, steady-state Grb2 protein
levels were documented. A significant reduction to 0.68-
fold levels was observed for Grb2 protein in seven WT vs.
eight KO mouse embryonal fibroblast (MEF) lines but not
in the mixed tissue cerebellum at adult age from nine WT
vs. nine KO mice (Fig. 4a). For Src, a similar effect with
significant reduction to 0.67-fold in MEF and a stronger
effect with significant reduction to 0.75-fold also in adult
cerebellum were observed (Fig. 4b). The analysis of the
dephosphorylated state of both sites in KO MEF again
showed a parallel trend towards upregulation. In adult KO
cerebellum, this parallel upregulation was significant. These
data indicate that a particularly strong reduction of Src
endogenous levels characterizes this ATXN2-KO tissue
with postmitotic neurons and that it is accompanied by
significantly less steady-state phosphorylation at both sites,
evidently balanced between the inactive and active states.
ATXN2 Deficiency Does Not Block Grb2-dependent Ras
Signaling
The association of Grb2 with RTK and SOS initiates sig-
naling in the Ras pathway (Fig. 1a), which depends on the
large mammalian Ras subfamily of small GTPases. In view
of a recent publication from semiquantitative immunocyto-
chemical data in a single SCA2 fibroblast line claiming that
pathogenic expansion of ATXN2 increases HRas expression
and that expanded ATXN2 effects on DNA damage are
antagonized by HRas silencing (Bertoni et al. 2011), we
used quantitative immunoblots and several fibroblast lines
from four SCA2 patients and seven ATXN2−/− mice, assess-
ing the expression levels of all three principal Ras family
members. In contrast to the report mentioned, for HRas,
KRas, and NRas, no significant expression changes were
detectable at the protein level in the murine or human
fibroblasts with ATXN2 mutations (Fig. 5a and b). The
discordance with the previous report might be attributed to
differences in cell line differentiation in ATXN2 expansion
lengths or to the assay tools employed.
For proliferation signaling, not only the RAS levels but
also the activation state is relevant. Ras-GTPases cycle
between their cytoplasmic inactive GDP form and their
plasma membrane-bound active GTP form (Hancock
2003). To further examine the role of ATXN2 in tissue
rather than cell lines and on the downstream Ras signaling
pathway, pull-down of total Ras and activated GTP-Ras was
performed in KO compared to WT cerebellum (Fig. 6a).
Since no relevant changes were detectable at steady-state in
tissue, we decided to assess dynamic alterations of Ras
activation, studying ATXN2−/− MEFs in a time course after
EGF stimulation. Ras activation was now documented through
the capability of Raf-1 to bind to GTP-Ras. Ras activation was
observed after 2 min of EGF stimulation, reached a peak at
5 min, and started to decrease by 10 min (Fig. 6b). No signif-
icant differences between KO and WT cells could be detected
at any of the time points. A major downstream effector target
of Ras-GTP is the MAP-kinase Raf-1 that activates the MEK/
Erk gene regulation cascade (Schlessinger 2000; Hancock
2003). Since MEK1 is expressed at much higher levels in the
brain than MEK2, we investigated the phosphorylation of
MEK1 in ATXN2−/− mice (Fig. 6c). After serum deprivation
of MEF over 24 h and EGF stimulation, changes in total and
phosphorylated MEK1 were documented by enzyme -linked
immunosorbent assay (ELISA). Consistent differences were
not detected. Altogether these data suggest that absence of
ATXN2 alone is not sufficient to significantly alter the Ras/
Erk pathway control of cell proliferation. These molecular
data are in agreement with cell biology studies, where signif-
icant differences in the doubling times were neither observed
between ATXN2−/− and control MEF nor between SCA2 and
control skin fibroblasts (data not shown).
Discussion
ATXN2 was previously shown to be constitutively associ-
ated with the RTK protein complex and to inhibit its endo-
cytic internalization via direct interaction with the SH3
motif-containing proteins endophilin A1, CIN85, and Src
(Ralser et al. 2005b; Nonis et al. 2008). However, it is
unclear whether these findings are relevant for proliferating
cells and carcinogenesis, or for the translation control in
postmitotic neurons and for neurodegenerative disorders.
A recent publication (Bertoni et al. 2011) claiming ATXN2
expansions to increase HRas expression and to be antago-
nized by HRas silencing resulting in the generation of DNA
damage, therefore, seemed to shed credible light on the
relationship between ATXN2 and cell stress.
Our present data show for the first time that ATXN2
indeed interacts with the SH3 motif containing protein
Grb2 in the endocytosis machinery and that ATXN2 loss-
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of-function and gain-of-function mutations in fibroblasts
modulate Grb2 protein levels. Grb2 is a broadly expressed
adaptor protein of 217 amino acids (25 kDa) that provides a
critical link between cell surface RTK and downstream
proliferation pathways (Downward 1994). While the gain
of function of Grb2 promotes cell proliferation and
transformation, decreased Grb2 function impairs developmen-
tal processes and Grb2 null mice are lethal at early embryonic
stage (Cheng et al. 1998; Tari and Lopez-Berestein 2001;
Giubellino et al. 2008). Grb2 is composed of two SH3 and
one SH2 motifs and can associate with activated tyrosine-
phosphorylated receptors via its SH2 domain (Fig. 2b); among
Fig. 5 ATXN2 mutations do
not influence endogenous RAS
expression levels in cultured
fibroblasts. a ATXN2
deficiency did not change
HRAS, KRAS, or NRAS
protein levels in MEFs (seven
WT vs. eight KO). As loading
control, β-actin was used in
immunoblots. b ATXN2 polyQ
expansion in SCA2 patient skin
fibroblasts also did not influ-
ence HRAS, KRAS, or NRAS
protein levels (four patient fi-
broblast lines vs. four control
fibroblast lines, n=2 for West-
ern blotting). As loading con-
trol, β-actin was used in
immunoblots. Representative
Western blots are shown for il-
lustration, and unpaired Stu-
dent’s t test was used for
statistical analysis (*p<0.05;
**p<0.01; ***p<0.001)
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these receptors are EGF, platelet-derived growth factor
(PDGF), and insulin receptors (Buday and Downward 1993;
Schlessinger 2000). Subsequently, Grb2 binds to Cbl and SOS
via its SH3 motifs to activate the Ras/Erk, phosphatidylinosi-
tol (PI)-3 kinase (PI3K) and ubiquitination–degradation path-
ways that control proliferation (van der Geer et al. 1994;
Gotoh 2008).
However, our analyses could not detect changes in the Ras
activation and downstream MEK1 phosphorylation, both in
tissue steady-state analyses and in cellular time course experi-
ments, contradicting current knowledge (Bertoni et al. 2011).
Our observations that ATXN2 expansions as well as ATXN2
deficiency result in mildly reduced levels of Grb2 and Src
protein while Ras signaling is not affected strongly byATXN2
deficiency provide a molecular basis for the previous obser-
vations (Wiedemeyer et al. 2003) that ATXN2 mutations
antagonize rather than promote carcinogenesis.
In SCA2 patient skin fibroblasts, both Grb2 and Src
protein levels appeared reduced in spite of a compensa-
tory upregulation of the transcripts. These data are com-
patible with two alternative concepts. ATXN2 expansions
could lead to altered stability of the endocytosis complex
with increased turnover and degradation of some compo-
nents, such as Grb2 and Src, insufficiently compensated
by enhanced synthesis. This scenario might suggest a
role of ATXN2 as scaffold for this protein complex.
Alternatively, ATXN2 expansions might impair the
mRNA translation rate, leading to reduced protein syn-
thesis in spite of compensatory high transcript levels. At
present, the interaction between ATXN2 and PABPC1
makes a role in mRNA translation credible, but it is
not clear whether the impact of mutations would be
inhibitory or stimulatory, and it is unclear which specific
mRNAs are regulated.
Fig. 6 Ras pathway signaling
appears unaffected by ATXN2.
a Ras pull-down experiments in
cerebellum of ATXN2−/− mice
showed no changes of total Ras
amounts. Cerebellum of 6-
month-old ATXN2−/− and WT
mice were dissected and direct-
ly frozen in liquid nitrogen prior
to the pull-down experiments
(10 KO vs. 10 WT). Tubulin
was used as loading control.
Statistical analysis was per-
formed with unpaired Student’s
t test (*p<0.05; **p<0.01;
***p<0.001). b Time course of
Ras activation in MEFs showed
no difference in absence of
ATXN2. KO and WT MEF
were serum deprived for 24 h
and afterwards stimulated with
100 ng/ml of EGF for the indi-
cated time (four WT vs. four
KO). The activation of Ras was
analyzed employing a Ras
GTPase activation ELISA kit
and measuring chemilumines-
cence. c MEK1 activation in
MEF was not modulated by
ATXN2 deficiency. KO and
WT MEF were serum deprived
for 24 h and stimulated with
100 ng/ml EGF for the indicat-
ed time (two WT vs. two KO).
The activation of MEK1 was
analyzed by ELISA. Total
amounts of MEK1 were not
different in KO compared to
WT mice
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It is very interesting that the decreased protein levels of
Grb2 and Src were not only caused by ATXN2 deficiency but
also by the ATXN2 polyQ expansion. While polyQ neurode-
generative diseases such as Huntington’s disease and spino-
bulbar muscle atrophy are known to be driven by a toxic gain
of function of the expanded protein, some disease features are
compatible with a partial loss of function of the disease protein
(Lieberman et al. 2002; Cary and La Spada 2008; Zuccato et al.
2010), indicating that multiple pathways of pathogenesis co-
exist. Thus, deficient RTK signaling may be expected to occur
in polyQ-ATXN2 modulated neural atrophies such as SCA2/
ALS/PSP. Src as a central hub for glutamate receptor regula-
tion modulates neural communication at a crucial step (Salter
andKalia 2004), while Grb2 via Erk is thought to influence the
volume and number of cells, neurites, and synapses (Vaudry et
al. 2002; Kelleher et al. 2004). In this context, it is interesting to
note that Grb2 through its SH3 motifs interacts also with
proline-rich motifs within huntingtin (Liu et al. 1997), the
disease protein responsible for the polyQ-mediated neurode-
generation Huntington’s disease. The polyQ expansion of
huntingtin leads to blockade of NGF receptor-mediated neurite
outgrowth in rat pheochromocytoma cells (Song et al. 2002).
Moreover, Grb2 was observed to interact with amyloid precur-
sor protein (APP) and presenilins 1 and 2, the disease proteins
responsible for Alzheimer’s dementia (Nizzari et al. 2007).
These observations strengthen the concept that RTK endocy-
tosis and signaling are relevant in neurodegenerative diseases.
Conclusions
Our data confirm the previously reported role of ATXN2 as an
interactor of SH3-motif proteins that modulate RTK endocy-
tosis (Nonis et al. 2008) and suggest a specific effect of
ATXN2 deficiency to reduce the levels of Grb2 and Src
proteins in mouse mutants. A novel analysis of patient skin
fibroblasts with ATXN2 polyQ expansion also detected re-
duced Grb2 and Src protein levels, compatible with the idea of
distorted RTK signaling as a modulator of neural atrophy in
human disease. However, the effects were found to be insuf-
ficient for a distortion of Ras signaling by themselves, in
disagreement with current literature, while they might act as
modifiers within the polygenic control of cell proliferation. A
more relevant role of ATXN2 may, therefore, lie in the many
neural signaling pathways controlled by Src.
Materials and Methods
Screen for ATXN2-interacting Proteins with SH3 Domain
Commercially available SH3 domain array membranes
(Panomics Inc., Fremont, CA, USA) were utilized to screen
for ATXN2 putative interacting proteins. The experiments
were performed according to the manufacturer’s instructions
with one modification. The big size of ATXN2 made ATXN2
unsuitable to be expressed in bacteria because the protein yield
is very low and the degradation products make up the majority
of the purified protein. Therefore, ATXN2 was expressed in
the mammalian system. Human Myc-ATXN2 was transiently
transfected with Lipofectamine 2000 (Invitrogen) in HEK-293
cells and after 24 h, protein extracts were dissolved in binding
buffer [150 mM NaCl, 10 mM HEPES pH7, 10 mM KCl,
5 mM MgCl2, 0.5 mM phenylmethanesulfonylfluoride
(PMSF), 1 % Igepal CA-630, protease inhibitor cocktail
(Roche)]. Myc-ATXN2 binding to the SH3 domains was
detected with anti-Myc antibody and the corresponding sec-
ondary horseradish peroxidase conjugate antibody.
Preparation of GST Fusion Proteins
Plasmid coding for GST-Grb2 and its subdomain fusion pro-
teins, GST-SH3 N, GST-SH3 C, GST-SH2, and GST-Raf1-
RDB, were introduced by heat pulse at 42 °C for 20 s into E.
coli BL21-Gold (DE3) pLysS (Stratagene, cat # 230134). For
the starting solutions, individual colonies were selected and
placed into 2 ml of 2XYTA medium in the presence of 50 μg/
ml ampicillin and 50 μg/ml chloramphenicol and incubated
overnight at 37 °C rotating at 250 rpm. The starter solution
was added to 150 ml of fresh 2XYTAmedium in the presence
of ampicillin and chloramphenicol and grown at 37 °C by
rotating at 250 rpm. The OD at 600 nm was measured every
30 min. When the OD reached 0.8–1, induction with isopro-
pyl β-D-1-thiogalactopyranoside (IPTG) 1 mM final concen-
tration was carried out for 3–4 h at 37 °C by rotating 250 rpm.
Then, the cells were collected and centrifuged for 15 min at
16,000 ×g at 4 °C. The pellet was resuspended in 4 ml of cold
phosphate buffered saline (PBS) with protease inhibitor cock-
tail (Roche) including 1 mM PMSF and incubated on ice for
20min. Afterwards, the cells were disrupted by sonication and
the subsequent addition of Triton X-100 to a final concentra-
tion of 0.5 %. The solution was incubated for 20 min on ice
and then centrifuged for 15 min at 16,000 ×g at 4 °C.
In Vitro Protein Binding Experiments with GST Fusion
Proteins
Glutathione sepharose 4B (Amersham Biosciences) beads
were washed once with PBS and then charged with extracts
containing GST fusion protein full length or subdomains.
The beads with the extracts were incubated with end-over-
end rotation for 1 h at 4 °C and then washed once with
binding buffer (25 mM HEPES pH8, 150 mM NaCl, 2 mM
MgCl2, 1 mM dithiothreitol (DTT), 5 % glycerol, 0.1 %
Igepal CA-630). Cell lysates or tissue homogenates previ-
ously dialyzed against binding buffer were added and
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incubated at 4 °C for 2 h or overnight with end-over-end
rotation. After extensive washing with binding buffer, bound
proteins were eluted by boiling in sodium dodecyl sulfate
(SDS) sample buffer and analyzed by Western blotting.
Mammalian Expression Vectors
Human ATXN2 cDNA was inserted as a NotI-KpnI frag-
ment (positions 172–4,348) (Pulst et al. 1996) into the N-
terminal tag vectors pCMV-HA and pCMV-Myc (BD Bio-
sciences) with the aid of a small oligonucleotide linker to
provide appropriate restriction sites and to adjust the reading
frame. In addition to the WT ATXN2 form with a (CAG)22
repeat, a pathogenic ATXN2 version with (CAG)74, was
fused to these vectors. 5′ and 3′ deletion variants of ATXN2
were cloned in pCMV-Myc. The remaining fragments of
ATXN2 were amplified by polymerase chain reaction (PCR)
and inserted into the N-terminal tag vector pCMV-Myc with
the addition of a small oligonucleotide linker to provide
appropriate restriction sites and to adjust the reading frame.
Cell Cultures and Transient Transfection
HEK-293 cells were grown in Dulbecco’s modified ea-
gle medium (DMEM) supplemented with 10 % fetal
calf serum (Sigma-Aldrich) under standard conditions.
HEK-293 cells were transfected with Lipofectamine
2000 (Invitrogen) according to the manufacturer’s
instructions. Transient expression over 48 h was used
for the preparation of protein extracts.
Embryonic skin fibroblasts from mice (MEFs) with con-
stitutive deletion of exon 1 of the ATXN2 gene resulting in
absence of ATXN2 mRNA and protein were isolated around
embryonal day 17 (Lastres-Becker et al. 2008a). Skin pieces
were minced in 3-cm Petri dishes and underwent enzymatic
digestion at 37 °C for 30 min in Falcon tubes with 1 ml
HyQTase (HyClone). The digested tissue was passed
through a 160 μm Nitex filter into 3-cm Petri dishes, and
the enzymes neutralized with DMEM + 15 % bovine growth
serum (Sigma-Aldrich). The resulting suspension was
centrifuged at 450×g for 5 min, and the cells were
plated at a density of 1×106 cells/cm2 in culture flasks.
The fibroblasts were placed in an incubator at 37 °C
supplemented with 5 % CO2, and the medium was
changed daily for the first 3 days. SCA2 patient fibro-
blasts were grown in DMEM supplemented with 15 %
fetal calf serum (Sigma-Aldrich), 1 % L-glutamine
(Gibco) and 1 % penicillin/streptomycin (Gibco).
Preparation of Protein Extracts and Immunoblotting
Mouse tissue or cells were lysed in 5 μl RIPA buffer per
milligram wet weight (50 mM Tris–HCl, pH8.0, 150 mM
NaCl, 1 mM ethylene diamine tetraacetic acid (EDTA), 1 mM
ethylene glycol tetraacetic acid (EGTA), 1 % Igepal CA-630,
0.5 % sodium deoxycholate, 0.1 % SDS, protease inhibitor
cocktail (Roche), and 1 mM PMSF). For coimmunoprecipita-
tion experiments, cellular extracts were prepared with a lysis
buffer containing 50 mM HEPES–NaOH, pH7.5, 150 mM
NaCl, 1 mM EDTA and 1 mM EGTA, 5 % glycerol, 0.1 %
Igepal CA-630, protease inhibitor cocktail (Roche), 1 mM
PMSF, and 1 mM NaF. Protein concentration was determined
using a BCA Protein Quantification Kit (Interchim) according
to the manufacturer’s protocol. Twenty micrograms of protein
per sample was separated on 7.5 % to 10 % polyacrylamide
gels followed by transfer to polyvinylidene fluoride (PVDF)
membranes. Blots were blocked with 5 % nonfat milk in PBS/
0.05 % Tween 20 for 1 h at room temperature and further
incubated with primary antibodies for 1 h at room temperature
(RT) or overnight at 4 °C. After washing the membranes,
immune complexes were detected with peroxidase-
conjugated anti-IgG secondary antibodies and SuperSignal
West Pico chemiluminescence substrate (Pierce), always with
a range of exposure times and selection of near-linear quanti-
fication. A densitometric analysis of the best immunoblots was
carried out using the program ImageJ (NIH). For quantifica-
tion, the protein expression changes were calculated by estab-
lishing the integrated density of each individual band. The
value measured for the protein of interest was divided by its
respective β-actin value. Bar graphs show the mean ± SEM of
normalized protein expression levels from all available control
or WT samples vs. the average protein expression level from
all available patient or KO samples. The following antibodies
were used: anti-ATXN2 (BD Biosciences), anti-Src (Cell Sig-
naling), anti-non-phospho Src (Tyr416) (Cell Signaling), anti-
non-phospho Src (Tyr527) (Cell Signaling), anti-Grb2 (BD
Biosciences), anti-HRas (Abcam), anti-KRas (Santa Cruz),
anti-NRas (Abcam), and anti-β-actin (Sigma-Aldrich).
Subcellular Fractionation and Coimmunoprecipitation
with Mouse Brain Tissue
Freshly dissected C57/BL6 mouse brains were disrupted with
a Dounce homogenizer in 5 vol./wet weight fractionation
buffer. Separation of cellular organelles by differential veloc-
ity centrifugation followed exactly the scheme given by Feng
et al. (1997), yielding fractions that predominantly contained
nuclei, mitochondria/heavy membranes, light membranes/
polysomes, and cytosol. The cytoplasmic fraction was con-
centrated using a centrifugal Amicon Ultra 30,000MWCO
filter device (Millipore) by centrifugation at 3,400 ×g for
45 min at 4 °C. The light membrane fraction was diluted in
binding buffer and then centrifuged at 16,000 ×g for 15 min at
4 °C and the supernatant stored for further immunoprecipita-
tion assays. Cytosolic and light membrane fractions were
incubated with appropriate amounts of antibodies overnight
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(approximately 12 μg/100–150 μl of tissue lysate). For the
immunoprecipitation of ATXN2, a commercial antibody (BD
Biosciences) was used. Antibody–protein complexes were
precipitated with protein G-agarose (for monoclonal antibod-
ies) at 4 °C for at least 2 h. The agarose beads were sedimented
by centrifugation and extensively washed with ice-cold bind-
ing buffer. The bead sediment was boiled in SDS sample
buffer, and the supernatant was analyzed by immunoblotting.
Coimmunoprecipitation with Transfected HEK-293 Cells
After 48 h of transfection, cells were washed once with cold
PBS and lysed in 500 μl of binding buffer per 10 cm
diameter dishes. The cells were incubated in binding buffer
for 10 min on ice, collected in 2 ml reaction tubes, and
centrifuged at 16,000 ×g for 10 min at 4 °C. The super-
natants were incubated with appropriate amounts of anti-
bodies for at least 2 h at 4 °C. Antibody–protein complexes
were precipitated with protein A/G or G-agarose at 4 °C
overnight. The agarose beads were sedimented by centrifu-
gation and extensively washed with ice-cold binding buffer.
The bead sediments were boiled in SDS sample buffer, and
the supernatants were analyzed by Western blotting. Anti-
Myc tag (BD Biosciences) and anti-ATXN2 (BD Bioscien-
ces) antibodies were used for the immunoprecipitations
(approximately 12 μg/300 μl of cell extract).
Enzyme-linked Immunosorbent Assay
Ras activation assays and phosphorylation of MEK1 were
investigated in ATXN2−/− MEFs after EGF stimulation. For
that purpose, a Ras GTPase activation ELISA kit (Millipore)
was employed and a MEK1/phospho-MEK1 ELISA kit
(Cell Signaling), respectively. Eighty percent of confluent
MEFs were serum deprived for 24 h and then stimulated for
different periods of time with 100 ng/ml of EGF. The
stimulation was stopped by transferring the Petri dishes with
MEFs on ice. The cell extraction and further steps were
carried out according to the manufacturer’s instructions.
Ras Pull-down Assay
Cerebellum of ATXN2-KO and WT mice obtained from 6-
month-old animals was used to perform the Ras pull-down
assay. Homogenized tissue (in 50 mM Tris–HCl, pH7.4,
100 mM NaCl, 2 mM MgCl2, 10 % glycerol, and 1 %
Nonidet P-40) was centrifuged at 14,000g, 4 °C, and the
supernatant was used for further experiments. The protein
concentration was determined using the DC protein assay
(Bio-Rad Laboratories). For the detection of total Ras, equal
amounts of proteins (10 μg/slot) were analyzed with SDS
polyacrylamide gel electrophoresis (SDS-PAGE) and West-
ern blotting. The immunoreactive bands were detected using
the primary antibody anti-Ras IgG (Upstate, diluted
1:10,000 in tris-buffered saline), anti-mouse horseradish
peroxidase-conjugated secondary antibody (Sigma-Aldrich)
and an enhanced chemiluminescence substrate detection kit
(Amersham Pharmacia Biotech). Blots were analyzed by
densitometric measurement and quantified using the pro-
gram ImageJ (NIH). Two hundred micrograms of protein
from lysates was used for Ras pull-down experiments,
which have been performed as described previously in detail
(de Rooij and Bos 1997; Lastres-Becker et al. 2008b). The
ratio between optic densities of GTP-Ras and total Ras
immunoblots served as an index for the relative levels of
active Ras within the probes. The band density was quanti-
fied using the program ImageJ (NIH).
RNA Preparation and First-strand cDNA Synthesis
RNA was extracted from cerebellum of 6-month-old
ATXN2−/−mice using the TRIzol reagent (Invitrogen) meth-
od. The extraction of RNA from cultured cells was done
using the RNeasy Mini Kit (Qiagen) according to the man-
ufacturer’s protocol.
One microgram total RNA was digested with DNase I
[1 U/μl] Amplication Grade and 10× DNaseI buffer
(Invitrogen) in reaction volumes of 10 μl. cDNA synthesis
was performed using a First-Strand cDNA Synthesis Kit
(SuperScript III, Invitrogen).
Quantitative Real-time RT-PCR
Twenty-five nanograms of cDNA was used to perform the
quantitative real-time RT-PCR (qRT-PCR) in a final reaction
volume of 20 μl. The expression analysis was carried out
using a StepOnePlus Real-Time PCR system (Applied Bio-
systems) and 96-well microplates (Applied Biosystems). All
reactions were carried out using the TaqMan Universal PCR
Master Mix (Applied Biosystems). Primers and probes for
TaqMan PCR were obtained from Applied Biosystems and
the following predesigned TaqMan Gene Expression Assays
we r e u s e d : GRB2 Hs00157817_m1 and SRC
Hs00178494_m1. The PCR conditions were 50 °C for 2 min
and 95 °C for 10 min followed by 40 cycles at 95 °C for 15 s
and 60 °C for 40 s. All assays were run in duplicate. An
analysis of relative gene expression data was performed using
the ΔΔCT method with TATA box binding protein (TBP)
(Hs99999910_m1) as endogenous control (Livak and
Schmittgen 2001).
Statistics
The statistical analyses were carried out with the GraphPad
software package (version 4.03, GraphPad Software Inc., San
Diego, CA, USA) to perform unpaired Student’s t tests when
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normal distribution and equal variances were fulfilled and to
display data as bar graphs, illustrating mean values and stan-
dard error of the mean (SEM). Significant differences were
highlighted with asterisks (*p<0.05; **p<0.01; ***p<0.001).
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